Loading...
•
Mar 31, 2023
Collegium Q1 2023 Earnings Report
Collegium's first quarter performance in 2023 was marked by record revenue and adjusted EBITDA, driven by lower Xtampza ER gross-to-net, record Belbuca revenues, and a synergized cost structure.
Key Takeaways
Collegium Pharmaceutical, Inc. reported record net revenue of $144.8 million in Q1 2023, a 73% increase year-over-year, and a GAAP net loss of $(17.4) million, with $(0.51) GAAP loss per share. The company ended the quarter with a cash balance of $269.5 million and reaffirmed its full-year 2023 guidance.
Generated record net revenue of $144.8 million.
Delivered record Belbuca and Xtampza ER net revenue.
Ended Q1 2023 with a cash balance of $269.5 million.
Reaffirmed full year 2023 guidance.
Forward Guidance
The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA.
Positive Outlook
- Product Revenues, Net: $565.0 to $580.0 million
- Adjusted Operating Expenses (Excluding Stock-Based Compensation): $135.0 to $145.0 million
- Adjusted EBITDA (Excluding Stock-Based Compensation): $355.0 to $370.0 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...